Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents
- PMID: 17680902
- DOI: 10.1111/j.1745-7599.2007.00236.x
Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents
Abstract
Purpose: The purposes of this study are threefold: to determine what components of the metabolic syndrome are present in obese adolescents, to determine what differences exist in the effects of lifestyle intervention versus lifestyle intervention plus metformin on weight management and select markers of metabolic syndrome in obese adolescents, and to determine which factors predict weight loss in obese adolescents treated with lifestyle changes and metformin.
Data sources: The study was a secondary data analysis utilizing a retrospective chart review of 63 obese adolescents aged 11 through 18 who were treated for obesity at the LeBonheur Youth Lifestyle Clinic from January 1, 2000, through June 30, 2005. Lifestyle interventions included diet, exercise, and counseling. The medication utilized was metformin. Outcomes evaluated included body mass index, relative body mass index (RBMI), weight, waist and hip circumference, blood pressure, serum lipid levels, fasting plasma glucose, 2-h oral glucose tolerance tests, and insulin levels. Changes in mean values between groups were evaluated using the General Linear Models procedure. Logistic regression was utilized to determine which factors might predict weight loss.
Conclusions: The metformin group (N= 37) tended to be heavier, older, and had more components of the metabolic syndrome than the nonmetformin group (N= 26). All components of the metabolic syndrome were present in both groups (overall prevalence 55%). Both groups had a downward trend in RBMI, a surrogate marker for weight loss, but only the metformin group had a significant loss in RBMI points from baseline to end. There was a trend toward better diastolic blood pressure at 6 months in the metformin group (p= 0.06), which was not seen in the nonmetformin group. The only predictors of weight loss were higher RBMI (those who were heavier lost more) and the absence of type 2 diabetes mellitus (type 2 DM) (those with type 2 DM were less likely to lose 10 or more points in RBMI).
Implications for practice: All components of the metabolic syndrome are present in obese adolescents. The use of lifestyle changes and lifestyle changes plus metformin both produce some degree of weight loss, but subjects on metformin in this study lost significantly more RBMI points than those on lifestyle changes alone. Subjects with type 2 DM are less likely to lose weight than those without type 2 DM. Larger studies and studies with subjects more representative of the general population need to be carried out to assist in the development of evidence-based practice guidelines.
Similar articles
-
Lifestyle plus exercise intervention improves metabolic syndrome markers without change in adiponectin in obese girls.Ann Nutr Metab. 2007;51(3):197-203. doi: 10.1159/000104137. Epub 2007 Jun 18. Ann Nutr Metab. 2007. PMID: 17587789 Clinical Trial.
-
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.Hum Reprod. 2006 Jan;21(1):80-9. doi: 10.1093/humrep/dei311. Epub 2005 Sep 30. Hum Reprod. 2006. PMID: 16199429 Clinical Trial.
-
Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention.Int J Obes (Lond). 2007 Jan;31(1):15-22. doi: 10.1038/sj.ijo.0803453. Epub 2006 Sep 5. Int J Obes (Lond). 2007. PMID: 16953257
-
Treatment of metabolic syndrome.Expert Rev Cardiovasc Ther. 2004 Mar;2(2):213-28. doi: 10.1586/14779072.2.2.213. Expert Rev Cardiovasc Ther. 2004. PMID: 15151470 Review.
-
Role of metformin for weight management in patients without type 2 diabetes.Ann Pharmacother. 2008 Jun;42(6):817-26. doi: 10.1345/aph.1K656. Epub 2008 May 13. Ann Pharmacother. 2008. PMID: 18477733 Review.
Cited by
-
METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study.Trials. 2014 Jun 5;15:207. doi: 10.1186/1745-6215-15-207. Trials. 2014. PMID: 24899137 Free PMC article. Clinical Trial.
-
Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure.J Dev Orig Health Dis. 2018 Jun;9(3):307-314. doi: 10.1017/S2040174417001118. Epub 2018 Jan 9. J Dev Orig Health Dis. 2018. PMID: 29310733 Free PMC article.
-
Role of Glucose-Lowering Medications in Erectile Dysfunction.J Clin Med. 2021 Jun 5;10(11):2501. doi: 10.3390/jcm10112501. J Clin Med. 2021. PMID: 34198786 Free PMC article. Review.
-
Preteen insulin levels interact with caloric intake to predict increases in obesity at ages 18 to 19 years: a 10-year prospective study of black and white girls.Metabolism. 2010 May;59(5):718-27. doi: 10.1016/j.metabol.2009.09.016. Epub 2009 Nov 14. Metabolism. 2010. PMID: 19913844 Free PMC article.
-
Prevalence of the metabolic syndrome among obese adolescents enrolled in a multidisciplinary weight management program: clinical correlates and response to treatment.Metab Syndr Relat Disord. 2009 Jun;7(3):179-86. doi: 10.1089/met.2008.0038. Metab Syndr Relat Disord. 2009. PMID: 19450141 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical